(TheNewswire)
Calgary, Alberta – TheNewswire - April 18,2024 – nDatalyze Corp.( “ NDAT ” or the “ Corporation”) (CSE:NDAT) (OTC:NDATF) is pleasedto announce an arm’s-length private placement ( “ PP ”) of 1,000,000 commonshares ( “ Shares ”) atUS$0.15 per Share (US$150,000). At a 1.375 exchange rate this equatesto approximately $206,250 Canadian Dollars and $0.21 per Sharesubscription price. A 6% finders fee of US$9,000 will be paid in cashto a third party and 90% of the net proceeds will be allocated to therecently-acquired Mindbalanced Inc. ( “ MB”)operations (NDAT acquired 100% of MB on April 16, 2024). The remainderwill be used for general working capital. There are no warrants orrights attached to the Shares and the Shares will be subject to aminimum four month hold period. The PP is subject to usual Board andRegulatory approvals.
Joshua Hill, President, reports: “ Gone are thedays of “ one-size-fits-all” mental conditiontreatments that too often result in poor patient outcomes. Ourmultivariate service provides personalized treatment protocols byintegrating advanced machine-learning assessment tools, genetics-baseddrug interaction panels and FDA-cleared, non-invasive, andnon-drug-dependent treatment protocols using Transcranial MagneticStimulation ( “ TMS”). Our primary customersare mental health-related facilities, clinics and clinicians who wantto provide effective and personalized treatment plans fordrug-resistant patients. We manage the entire program and ourrevenue-sharing business model benefits our customers by saving time,providing state-of-the-art tools, offering personalized treatmentprotocols, and adding an additional revenue stream. We expect thatrevenues from private and public medical insurance programs will growsignificantly as mental health benefits are added to more insuranceplans. Importantly, we expect to add significant amounts of biometric,DNA, and TMS treatment response data to YMI which we believe will beinvaluable in developing personalized treatment protocols goingforward. All of this adds up to high levels of interest from alllevels of our market.”
MB also reports that Dr. Laura Champagne, Psychiatrist from Texas, andDr. Yvonka De Ridder from Florida, have recently joined our esteemedteam through signed contracts.
For Further Information about thistransaction, please contact:
Joshua Hill, President
Email: josh@mindbalanced.org
Mindbalanced website: https://mindbalanced.org/
nDatalyze website: https://www.ndatalyze.com
About Mindbalanced, Inc.: Mindbalanced’s vision is to redefine mentalhealthcare through an integrative, personalized approach leveragingcutting edge technology and non-invasive treatment protocols. Byharnessing evidence-based data we aim to predict and enhance mentalwellbeing, taking into account individual predispositions andenvironmental factors thereby fostering healthier and more fulfillinglives for all.
About YMI: YMIuses evidence-based, objective data from whole life experiences topredict individual mental states over time and applies this knowledgetowards a fuller understanding of how mental health develops, and howto improve mental wellbeing. YMI combines supervised machine-learningwith a proprietary Reference Database to predict an individual’spredisposition toward a variety of common mental conditions, bothcurrent and forward in time. YMI is poised to revolutionizemental health diagnoses while ensuring a sustainable revenue stream.By strategically addressing the causes of misdiagnosis, establishingcredibility through clinical studies, and targeting key markets, YMIaligns both societal impact and financial success.
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in the policiesof the Canadian Securities Exchange) accepts responsibility for theadequacy or accuracy of this release. This news release does notconstitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. Thesecurities have not been and will not be registered under the UnitedStates Securities Act of 1933, as amended (the "U.S. SecuritiesAct") or any state securities laws and may not be offered or soldwithin the United States or to U.S. Persons unless registered underthe U.S. Securities Act and applicable state securities laws or anexemption from such registration is available. The information in thisnews release includes certain information and statements aboutmanagement's view of future events, expectations, plans and prospectsthat constitute forward looking statements. These statements are basedupon assumptions that are subject to significant risks anduncertainties. Because of these risks and uncertainties and as aresult of a variety of factors, the actual results, expectations,achievements or performance may differ materially from thoseanticipated and indicated by these forward-looking statements. Anynumber of factors could cause actual results to differ materially fromthese forward-looking statements as well as future results. Althoughthe Corporation believes that the expectations reflected in forwardlooking statements are reasonable, it can give no assurances that theexpectations of any forward-looking statements will prove to becorrect. Except as required by law, the Corporation disclaims anyintention and assumes no obligation to update or revise anyforward-looking statements to reflect actual results, whether as aresult of new information, future events, changes in assumptions,changes in factors affecting such forward-looking statements orotherwise.
Copyright (c) 2024 TheNewswire - All rights reserved.